Sanofi Lantus brand insulin pens are arranged for a photo on April 5, 2019 in Brooklyn, New York.
Alex Flynn | Bloomberg | Getty Images
Americans now have access regardless of their insurance status Sanofiis the most commonly prescribed insulin for $35 through the Prescription Drug Savings Association GoodRxthe companies announced Thursday.
Patients with a valid prescription can specifically access a $35 voucher for Sanofi’s Lantus on the GoodRx website and redeem it at more than 70,000 retail pharmacies across the United States CVS, Walgreens And Walmart.
The effort aims to make Lantus’ $35 price tag more accessible to Americans, even after Sanofi — along with its competitors Eli Lilly And Novo Nordisk – announced sweeping price cuts for insulin and cost caps for out-of-pocket costs earlier this year.
These three companies, which control more than 90% of the global insulin market, have moved to cut prices after years of political pressure and public outrage over the high cost of diabetes care in the United States about eight times more for insulin than other industrialized countries, which makes diabetes a national issue most expensive chronic illness.
Sanofi announced in March that it would lower list prices for Lantus and cap the deductible for insured people at $35 per month. However, the change will not take effect until January.
The French company also has an existing patient assistance program to cap insulin prices at the same price for uninsured diabetes patients. However, some patients had difficulty meeting the $35 price tag despite this program.
This is due to patients’ low awareness of copay cards and patient savings programs that can help with out-of-pocket costs. Health experts and patient advocates have raised concerns about this these programsthat manufacturers offer often require people to jump through hoops just to save money.
According to a study, pharmaceutical companies spend more than $5 billion each year marketing patient support programs, but only 3% of patients actually use them Survey 2021 from Phreesia Life Sciences.
President Joe Biden’s Inflation Reduction Act also capped monthly insulin costs at $35 for those with Medicare, but did not provide protection for diabetes patients who have private insurance.
According to this, about 37 million people in the USA, or 11.3% of the country’s population, suffer from diabetes Centers for Disease Control and Prevention. Approximately 8.4 million diabetes patients rely on insulin American Diabetes Association said.
Don’t miss these CNBC PRO stories: